quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·30d
PRRelease
AbbVie Inc. logo
Landos Biopharma Inc. logo

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

ABBV· AbbVie Inc.LABP· Landos Biopharma Inc.
Health Care
Original source

Companies

  • ABBV
    AbbVie Inc.
    Health Care
  • LABP
    Landos Biopharma Inc.
    Health Care

Recent analyst ratings

  • Apr 21ABBVUpdateCanaccord Genuity$262.00
  • Feb 25ABBVUpdateRBC Capital Mkts$260.00
  • Feb 20ABBVUpdateBarclays$275.00
  • Jan 8ABBVUpdateWolfe Research-
  • Jan 7ABBVUpdateUBS$240.00
  • Dec 10ABBVUpdateHSBC Securities$265.00

Related

  • PR7h
    AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
  • PR1d
    AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
  • ANALYST2d
    Canaccord Genuity initiated coverage on AbbVie with a new price target
  • PR3d
    AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
  • PR9d
    Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
  • PR10d
    Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
  • PR11d
    AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
  • PR15d
    BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022